Sanofi and Six Other Companies Partner to Speed Up Development of New TB Medicines
Seven pharmaceutical companies, including Sanofi and four research institutions, working with the Bill & Melinda Gates Foundation, have entered into a partnership to speed up the discovery of essential new treatments for tuberculosis (TB). The partnership, known as the TB Drug Accelerator (TBDA), will target the discovery of new TB drugs by collaborating on early-stage research.
Click to learn more about Sanofi's involvement in developing new TB medications at PharmaBiz.
About Sanofi
Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms; diabetes solutions, human vaccine, innovation drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).
Sanofi is the holding company of a consolidated group of subsidiaries and operates in the United States as Sanofi US, also referred to as sanofi-aventis U.S> LLC. For more information on Sanofi US, please visit http//www.sanofi.us (http://www.sanofi.us) or call 1-800-981-2491.
